Fadi Haddad, Assistant Professor at The University of Texas MD Anderson Cancer Center, shared a paper Jennifer R. Brown and colleagues authored on X:
“AMPLIFY Ph 3 trial
867 patients, median age 61 yrs, ND CLL
No TP53/del17p, unmutated IGHV 59%
Acala+Ven x1 yr (AV) AV x1 yr + Obin x6 mo (AVO) Chemo-immunotherapy (CT)
3-year PFS: 77% AV versus 83% AVO versus 67% CT.”
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
Authors: Jennifer R. Brown et al.
